Caris Life Sciences announced a new AI signature that predicts early platinum resistance in patients with high‑grade serous ovarian cancer (HGSOC). The signature, added to the Caris AI Insights portfolio, analyzes whole‑exome and whole‑transcriptome sequencing data to generate a risk score and a platinum‑sensitive or platinum‑resistant prediction.
The tool produces Kaplan‑Meier curves that help oncologists estimate how long a patient may benefit from first‑line platinum‑based chemotherapy. It is available now through the Caris Molecular Tumor Board Report when ordering the company’s MI Cancer Seek assay, which received FDA approval as a companion diagnostic on November 6, 2024.
The launch aligns with the February 10, 2026 FDA approval of pembrolizumab plus paclitaxel, with or without bevacizumab, for platinum‑resistant ovarian cancer. By identifying patients likely to develop early platinum resistance, the signature supports timely treatment adjustments and opens a new therapeutic pathway for the 20‑30% of advanced HGSOC patients who develop resistance.
Caris’s CodeAI platform powers the signature, leveraging an extensive real‑world dataset to deliver actionable insights. The addition strengthens Caris’s position as a leader in AI‑driven precision oncology and expands the clinical utility of its MI Cancer Seek assay.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.